Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relmacabtagene Autoleucel Injection Followed by Tislelizumab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Involved in the Central Nervous System

NCT06876688 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06876688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06876688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relmacabtagene Autoleucel Injection Followed by Tislelizumab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Involved in the Central Nervous System
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 30, 2023
Completion date
November 30, 2028
Enrollment
30 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cns lymphoma